PatentVest's report analyzes trends and innovations in the expanding CGM market, highlighting key players and future opportunities.
Quiver AI Summary
PatentVest has published a report titled "Continuous Glucose Monitoring (CGM): An Evolving Innovation Landscape," which examines the rapidly growing CGM market, crucial for managing diabetes, a condition impacting 537 million adults globally as of 2021 and expected to rise significantly by 2045. The CGM market is currently valued at approximately $11.63 billion and is anticipated to reach $21 billion by 2029, driven by advancements in technology and the introduction of non-invasive, over-the-counter monitoring solutions. The report details the impact of technological innovations, market dynamics, and the importance of intellectual property strategies in this sector, highlighting key players like Dexcom, Abbott, Medtronic, and Roche. PatentVest aims to provide actionable insights for stakeholders navigating this evolving landscape, emphasizing the critical role of CGMs in enhancing diabetes management and patient outcomes.
Potential Positives
- PatentVest is positioned as a thought leader in the CGM market by releasing a comprehensive report that provides valuable insights into trends, key players, and opportunities for stakeholders.
- The report highlights the projected growth of the CGM market from $11.63 billion in 2024 to $21 billion by 2029, emphasizing significant market potential that could benefit PatentVest and its clients.
- As the CGM market experiences a surge in patent filings and innovation, PatentVest's expertise in intellectual property strategy positions it to assist clients in navigating this competitive landscape effectively.
Potential Negatives
- The report indicates a highly competitive and rapidly evolving market, potentially challenging PatentVest's position and ability to maintain a leading edge in IP intelligence and strategy.
- The mention of ongoing litigation trends suggests a contentious environment within the CGM market, which could reflect negatively on the stability and potential risks associated with the sector.
- The dependence on technological advancements and a surge in patent filings may imply that PatentVest risks being viewed solely as a service provider in a fast-paced field rather than an innovator, potentially affecting its perceived value among clients and investors.
FAQ
What is the new PatentVest report about?
The report analyzes the evolving Continuous Glucose Monitoring (CGM) market, highlighting trends, key players, and future opportunities in diabetes care.
How large is the CGM market projected to be?
The CGM market is projected to grow from $11.63 billion in 2024 to $21 billion by 2029, driven by technological advancements.
Who are the key players in the CGM market?
Major players include Dexcom, Abbott, Medtronic, and Roche, who are leading innovations in diabetes management solutions.
What drives the demand for Continuous Glucose Monitors?
Rising diabetes prevalence, the complexity of management, and the need for real-time monitoring drive demand for CGMs in healthcare.
How can I access the full PatentVest report?
The full report is available for access online, providing detailed insights into the CGM market dynamics and innovations.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MDBH Insider Trading Activity
$MDBH insiders have traded $MDBH stock on the open market 13 times in the past 6 months. Of those trades, 4 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $MDBH stock by insiders over the last 6 months:
- ANTHONY DIGIANDOMENICO (Co-Founder) has traded it 4 times. They made 4 purchases, buying 4,048 shares and 0 sales.
- JEREMY WILLIAM JAMES (CFO) has traded it 9 times. They made 0 purchases and 9 sales, selling 6,661 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MDBH Hedge Fund Activity
We have seen 3 institutional investors add shares of $MDBH stock to their portfolio, and 4 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BAKER AVENUE ASSET MANAGEMENT, LP removed 75,000 shares (-100.0%) from their portfolio in Q3 2024
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 14,593 shares (-100.0%) from their portfolio in Q3 2024
- BLACKROCK, INC. added 6,946 shares (+186.1%) to their portfolio in Q3 2024
- UBS GROUP AG added 5,739 shares (+22.0%) to their portfolio in Q3 2024
- TOTH FINANCIAL ADVISORY CORP removed 400 shares (-100.0%) from their portfolio in Q3 2024
- PASADENA PRIVATE WEALTH, LLC added 200 shares (+0.3%) to their portfolio in Q3 2024
- TOWER RESEARCH CAPITAL LLC (TRC) removed 157 shares (-100.0%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Addison, TX, Jan. 07, 2025 (GLOBE NEWSWIRE) -- PatentVest, a leader in intellectual property (IP) intelligence and strategy, has released its latest report, “
Continuous Glucose Monitoring (CGM): An Evolving Innovation Landscape
.” This in-depth analysis explores the rapidly growing CGM market, offering valuable insights into the trends, key players, and opportunities that are shaping the future of diabetes care.
Diabetes is one of the most pressing global health challenges, affecting an estimated 537 million adults worldwide in 2021—a number projected to rise to 783 million by 2045. As the complexity of diabetes management grows, the need for continuous, real-time glucose monitoring has never been more critical. Continuous Glucose Monitors (CGMs) address these challenges by providing patients with timely insights into their glucose levels, enabling more informed decision-making and better health outcomes.
Valued at $11.63 billion in 2024, the CGM market is projected to reach $21 billion by 2029, driven by technological advancements, greater accessibility, and the growing availability of non-invasive, over-the-counter (OTC) solutions.
Key Factors Shaping the Market:
Technological Advancements:
Innovations in CGM technology, including non-invasive glucose monitoring and seamless integration with mobile applications, are improving the convenience, accuracy, and accessibility of diabetes care.
Market Dynamics:
The emergence of OTC CGM products is broadening access to diabetes care, particularly for non-insulin-dependent patients and wellness-focused individuals, creating a significant shift in the market.
Intellectual Property Strategy:
The CGM market is characterized by a surge in patent filings, as companies race to protect their innovations and secure leadership positions. Ongoing litigation trends further highlight the high stakes in this rapidly evolving market.
“While there is currently no simple cure for diabetes, this report provides key insights into how major players like Dexcom, Abbott, Medtronic, and Roche are advancing innovative solutions to transform diabetes management,” said Will Rosellini, Chief IP Officer at PatentVest. “Through technological advancements, strategic market moves, and evolving IP strategies, these companies are shaping the future of diabetes care and expanding access to critical monitoring tools.”
PatentVest’s report provides in-depth analysis of these factors and offers actionable insights for companies, investors, and healthcare leaders navigating the CGM space.
Access the Full Report
The PatentVest Pulse report is now available. Gain comprehensive insights into the trends, technologies, and competitive dynamics driving the CGM market:
Access the full report here
.
For more information or inquiries, please contact
info@patentvest.com
.
About PatentVest
PatentVest, a division of MDB Capital Holdings (Nasdaq: MDBH), is the first integrated IP intelligence, strategy, and law firm to enable visionary companies to develop into technology leaders. By combining our proprietary database with a time proven IP diligence process and expert analysis, we deliver actionable insights on the IP landscape to help our clients make informed decisions and stay ahead of the curve. The trends and competitive insights in this report are powered by PatentVest's proprietary IP intelligence platform. Our reports keep a pulse on the key players, technologies, and opportunities shaping deep technology markets.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
